blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3555135

EP3555135 - IL-11RA ANTIBODIES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.02.2025
Database last updated on 21.03.2026
FormerThe patent has been granted
Status updated on  08.03.2024
FormerGrant of patent is intended
Status updated on  24.10.2023
FormerExamination is in progress
Status updated on  24.06.2020
FormerRequest for examination was made
Status updated on  20.09.2019
FormerThe international publication has been made
Status updated on  23.06.2018
Formerunknown
Status updated on  10.02.2018
Most recent event   Tooltip24.10.2025Lapse of the patent in a contracting state
New state(s): CH, IE		published on 26.11.2025  [2025/48]
Applicant(s)For all designated states
Singapore Health Services Pte Ltd
31 Third Hospital Avenue
03-03 Bowyer Block C
Singapore 168753 / SG
For all designated states
National University of Singapore
21 Lower Kent Ridge Road
Singapore 119077 / SG
[2019/43]
Inventor(s)01 / COOK, Stuart Alexander
6 Sunset Square
Clementi Park
Singapore 597304 / SG
02 / SCHAEFER, Sebastian
76 Shenton Way
76 Shenton 24-04
Singapore 079119 / SG
 [2019/43]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2024/15]
Former [2019/43]Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
Application number, filing date17836010.315.12.2017
[2019/43]
WO2017EP83043
Priority number, dateGB2016002143916.12.2016         Original published format: GB 201621439
[2019/43]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2018109170
Date:21.06.2018
Language:EN
[2018/25]
Type: A2 Application without search report 
No.:EP3555135
Date:23.10.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 21.06.2018 takes the place of the publication of the European patent application.
[2019/43]
Type: B1 Patent specification 
No.:EP3555135
Date:10.04.2024
Language:EN
[2024/15]
Search report(s)International search report - published on:EP30.08.2018
ClassificationIPC:C07K16/28
[2019/43]
CPC:
C07K16/244 (EP,KR,US); C07K16/2866 (EP,KR,US); A61P17/02 (EP,KR,US);
A61P35/00 (EP,KR,US); A61P43/00 (EP,KR,US); C07K14/5431 (EP,KR,US);
C07K14/7155 (EP,KR,US); G01N33/6854 (US); G01N33/6869 (EP,KR,US);
A61K2039/505 (EP,KR,US); C07K2317/24 (EP,KR,US); C07K2317/76 (EP,KR,US);
C07K2317/92 (EP,KR,US); C07K2319/32 (EP,KR,US); C07K2319/75 (EP,KR,US);
G01N2333/7155 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/43]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:IL-11RA-ANTIKÖRPER[2019/43]
English:IL-11RA ANTIBODIES[2019/43]
French:ANTICORPS IL-11RA[2019/43]
Entry into regional phase04.07.2019National basic fee paid 
04.07.2019Designation fee(s) paid 
04.07.2019Examination fee paid 
Examination procedure19.10.2018Request for preliminary examination filed
International Preliminary Examining Authority: EP
04.07.2019Examination requested  [2019/43]
04.07.2019Date on which the examining division has become responsible
30.01.2020Amendment by applicant (claims and/or description)
29.06.2020Despatch of a communication from the examining division (Time limit: M06)
07.01.2021Reply to a communication from the examining division
14.02.2023Despatch of a communication from the examining division (Time limit: M04)
14.06.2023Reply to a communication from the examining division
25.10.2023Communication of intention to grant the patent
29.02.2024Fee for grant paid
29.02.2024Fee for publishing/printing paid
29.02.2024Receipt of the translation of the claim(s)
Opposition(s)13.01.2025No opposition filed within time limit [2025/12]
Fees paidRenewal fee
06.12.2019Renewal fee patent year 03
22.12.2020Renewal fee patent year 04
17.12.2021Renewal fee patent year 05
16.12.2022Renewal fee patent year 06
20.12.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
IT10.04.2024
LV10.04.2024
MC10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SE10.04.2024
SI10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
IE15.12.2024
LU15.12.2024
BE31.12.2024
CH31.12.2024
[2025/48]
Former [2025/47]AT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
IT10.04.2024
LV10.04.2024
MC10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SE10.04.2024
SI10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
LU15.12.2024
BE31.12.2024
Former [2025/42]AT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
IT10.04.2024
LV10.04.2024
MC10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SE10.04.2024
SI10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
LU15.12.2024
Former [2025/39]AT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
IT10.04.2024
LV10.04.2024
MC10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SI10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
LU15.12.2024
Former [2025/33]AT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
IT10.04.2024
LV10.04.2024
MC10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SI10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2025/22]AT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
IT10.04.2024
LV10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SI10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2025/11]AT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
IT10.04.2024
LV10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2025/10]AT10.04.2024
BG10.04.2024
CZ10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
LV10.04.2024
NL10.04.2024
PL10.04.2024
RO10.04.2024
SK10.04.2024
SM10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2025/09]AT10.04.2024
BG10.04.2024
DK10.04.2024
EE10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
LV10.04.2024
NL10.04.2024
PL10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2025/08]AT10.04.2024
BG10.04.2024
DK10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
LV10.04.2024
NL10.04.2024
PL10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2024/49]AT10.04.2024
BG10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
LV10.04.2024
NL10.04.2024
PL10.04.2024
NO10.07.2024
RS10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2024/48]AT10.04.2024
BG10.04.2024
ES10.04.2024
FI10.04.2024
HR10.04.2024
NL10.04.2024
NO10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2024/47]BG10.04.2024
FI10.04.2024
HR10.04.2024
NL10.04.2024
NO10.07.2024
GR11.07.2024
IS10.08.2024
PT12.08.2024
Former [2024/46]BG10.04.2024
FI10.04.2024
HR10.04.2024
NL10.04.2024
NO10.07.2024
IS10.08.2024
Former [2024/44]NL10.04.2024
Cited inInternational search[XY] WO2014121325  (CSL LTD et al.)
 [A] WO2017103108  (SINGAPORE HEALTH SERV PTE LTD et al.)
 [IY]   RAY ET AL: "Regulated overexpression of interleukin 11 in the lung", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 100, no. 10, 1 November 1997 (1997-11-01), pages 2501 - 2511, XP002110021, ISSN: 0021-9738, DOI: 10.1172/JCI119792 [I] 1-10,14-21,24,26,28,35,36 * The whole document, in particular, Fig.4 *[Y] 22-28

DOI:   http://dx.doi.org/10.1172/JCI119792
 [A]   LYNNE A. MURRAY ET AL: "Targeting Interleukin-13 with Tralokinumab Attenuates Lung Fibrosis and Epithelial Damage in a Humanized SCID Idiopathic Pulmonary Fibrosis Model", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY., vol. 50, no. 5, 1 May 2014 (2014-05-01), NEW YORK, NY, US, pages 985 - 994, XP055472908, ISSN: 1044-1549, DOI: 10.1165/rcmb.2013-0342OC [A] 1 * the whole document *

DOI:   http://dx.doi.org/10.1165/rcmb.2013-0342OC
 [XY]   CHUN GEUN LEE ET AL: "Endogenous IL-11 Signaling Is Essential in Th2- and IL-13-Induced Inflammation and Mucus Production", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY., vol. 39, no. 6, 1 December 2008 (2008-12-01), NEW YORK, NY, US, pages 739 - 746, XP055472906, ISSN: 1044-1549, DOI: 10.1165/rcmb.2008-0053OC [Y] 22,24,26

DOI:   http://dx.doi.org/10.1165/rcmb.2008-0053OC
 [Y]   WEILIANG TANG ET AL: "Transforming Growth Factor-[beta] Stimulates Interleukin-11 Transcription via Complex Activating Protein-1-dependent Pathways", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 10, 6 March 1998 (1998-03-06), US, pages 5506 - 5513, XP055472902, ISSN: 0021-9258, DOI: 10.1074/jbc.273.10.5506 [Y] 22,24,26 * The whole document, in particular, the abstract;; figures 6.D,E *

DOI:   http://dx.doi.org/10.1074/jbc.273.10.5506
 [A]   JULIANE LOKAU ET AL: "Proteolytic Cleavage Governs Interleukin-11 Trans-signaling", CELL REPORTS, vol. 14, no. 7, 1 February 2016 (2016-02-01), US, pages 1761 - 1773, XP055453739, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2016.01.053 [A] 22,24,26 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.celrep.2016.01.053
 [A]   ZONG-JIANG G ET AL: "Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 190, no. 1, 28 March 1996 (1996-03-28), pages 21 - 27, XP004020885, ISSN: 0022-1759, DOI: 10.1016/0022-1759(95)00232-4 [A] 22,24,26 * the whole document *

DOI:   http://dx.doi.org/10.1016/0022-1759(95)00232-4
 [A]   SEBASTIAN SCHAFER ET AL: "IL-11 is a crucial determinant of cardiovascular fibrosis", NATURE, 7 December 2017 (2017-12-07), London, XP055472896, ISSN: 0028-0836, DOI: 10.1038/nature24676 [A] 22,24,26 * the whole document *

DOI:   http://dx.doi.org/10.1038/nature24676
Examination  JOHNSTONE CAMERON N ET AL: "Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer", CYTOKINE & GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 26, no. 5, 14 July 2015 (2015-07-14), pages 489 - 498, XP029276469, ISSN: 1359-6101, DOI: 10.1016/J.CYTOGFR.2015.07.015

DOI:   http://dx.doi.org/10.1016/j.cytogfr.2015.07.015
   J. SOMMER ET AL: "Constitutively Active Mutant gp130 Receptor Protein from Inflammatory Hepatocellular Adenoma Is Inhibited by an Anti-gp130 Antibody That Specifically Neutralizes Interleukin 11 Signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 17, 20 April 2012 (2012-04-20), US, pages 13743 - 13751, XP055380778, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.349167

DOI:   http://dx.doi.org/10.1074/jbc.M111.349167
   ROBERTO M. LEMOLI ET AL: "Interleukin-11 (IL-11) acts as a synergistic factor for the proliferation of human myeloid leukaemic cells", BRITISH JOURNAL OF HAEMATOLOGY, vol. 91, no. 2, 1 October 1995 (1995-10-01), Hoboken, USA, pages 319 - 326, XP055473434, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.1995.tb05296.x

DOI:   http://dx.doi.org/10.1111/j.1365-2141.1995.tb05296.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.